Thymoquinone inhibits epithelial-mesenchymal transition in prostate cancer cells by negatively regulating the TGF-β/Smad2/3 signaling pathway

BO KOU1*, WEI LIU2*, WEI ZHAO3*, PENG DUAN4, YANG YANG1, QIUYUE YI1, FENGWEI GUO1, JIANPENG LI1, JINSONG ZHOU5,6 and QINGSHAN KOU7

Departments of 1Cardiovascular Surgery, 2Urology, 3General Surgery and 4The First Affiliated Hospital of the Medical School, Xi’an Jiaotong University, Xi’an, Shaanxi 710061; 5Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Xi’an Jiaotong University Health Science Center, Xi’an, Shaanxi 710061; 6Key Laboratory of Environment and Genes Related to Diseases, Xi’an Jiaotong University, Ministry of Education of China, Xi’an, Shaanxi 710061; 7Medical Center, First People’s Hospital of Xianyang, Xianyang, Shaanxi 712000, P.R. China

Received April 11, 2017; Accepted September 20, 2017

DOI: 10.3892/or.2017.6012

Correspondence to: Professor Jinsong Zhou, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Xi’an Jiaotong University Health Science Center, 76 West Yanta Road, Xi’an, Shaanxi 710061, P.R. China
E-mail: zjs301@mail.xjtu.edu.cn

Dr Qingshan Kou, Medical Center, First People’s Hospital of Xianyang, Xianyang, Shaanxi 712000, P.R. China
E-mail: 492526094@qq.com

*Contributed equally

Key words: thymoquinone, prostate cancer, migration, invasion, epithelial-mesenchymal transition, TGF-β

Abstract. Thymoquinone, a major ingredient of black seed oil (Nigella sativa), has been shown to exhibit anticancer capacity in various types of cancers. However, there are few studies concerning the correlation between thymoquinone and epithelial-to-mesenchymal transition (EMT) in prostate cancer. In the present study, we firstly found that thymoquinone showed antimetastatic capacity in prostate cancer DU145 and PC3 cells. Additionally, thymoquinone reversed EMT by increasing E-cadherin expression and decreasing vimentin and Slug expression in a concentration-dependent manner. Recent studies have shown that the transforming growth factor-β (TGF-β) signaling pathway may be associated with EMT. Intriguingly, the expression of TGF-β, Smad2 and Smad3 at the mRNA and protein levels was notably reduced upon thymoquinone treatment in prostate cancer DU145 and PC3 cells. Subsequently, we confirmed that thymoquinone repressed metastasis and EMT of prostate cancer through downregulation of the TGF-β/Smad2/3 signaling pathway, which may be partially reversed by TGF-β overexpression. In summary, our findings demonstrated that thymoquinone suppressed the metastatic phenotype and reversed EMT of prostate cancer cells by negatively regulating the TGF-β/Smad2/3 signaling pathway. These findings suggest that thymoquinone is a potential therapeutic agent against prostate cancer which functions by targeting TGF-β.

Introduction

Prostate cancer is the most lethal urogenital system malignancy in men, accounting for an estimated 161,360 new cases and 26,730 deaths in the US in 2017 (1). Although great improvement has been made in the efficacy of therapeutic methods, most prostate cancer develops into a metastatic pattern, which is a major obstacle for the treatment of prostate cancer (2). Recent research has reported that epithelial-to-mesenchymal transition (EMT) is a necessity for the invasion-metastasis cascade of cancer (3). EMT is a complicated process which involves the loss of epithelial characteristics and acquisition of a mesenchymal phenotype, contributing to the initiation of the metastatic cascade (4). Given that there are few effective therapeutic methods for the treatment of cancer metastasis, the development of novel therapeutic agents against prostate cancer is critically needed.

Thymoquinone (TQ), a major ingredient of black seed oil (Nigella sativa), has been shown to exhibit broad pharmacologic effects, such as anti-inflammatory (5) and antioxidant activity (6). Moreover, thymoquinone has been reported to possess antineoplastic activity against various cancers, including pancreatic (7), lung (8) and colon cancer (9) and leukemia (10). Studies have shown that thymoquinone inhibits the growth and induces cell apoptosis and cycle arrest, as well as represses metastasis and angiogenesis, which involves Akt (11), NF-κB signaling (12), mitogen-activated protein kinase (MAPK) (13) and STAT3 signaling pathways (14).

In prostate cancer C4-2B and PC3 cells, thymoquinone was found to suppress proliferation via the accumulation of reactive oxygen species (ROS) and reduction in the glutathione (GST) level (15). However, there is no study concerning the correlation between thymoquinone and EMT in prostate
cancer. In addition, the underlying mechanism by which thymoquinone suppresses the metastatic phenotype has not yet been elucidated. The present study aimed to explore the potential capacity of thymoquinone to reverse EMT in prostate cancer cells and the related mechanism.

Materials and methods

Reagents and cell culture. Thymoquinone (C10H12O2) was purchased from Sigma-Aldrich (St. Louis, MO, USA) and dissolved in dimethyl sulfoxide (DMSO). Stock solutions were stored at -20°C. Antibodies against transforming growth factor-β (TGF-β), Smad2, Smad3, E-cadherin, vimentin, Slug and β-actin were purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Sigma Chemical Co. (St. Louis, MO, USA).

Human prostate cancer cell lines DU145 and PC3 were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). These two cell lines were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY, USA), 100 µg/ml streptomycin and 100 U/ml penicillin (Invitrogen, Carlsbad, CA, USA) at 37°C in a humidified incubator with 5% CO2.

Cell proliferation assay. A modified MTT assay was used to evaluate cell proliferation. In brief, DU145 and PC3 cells were seeded at a density of 1.2x10^4/well in 96-well plates with 90% density and subsequently exposed to increasing concentrations of thymoquinone for 24 h. Then, 20 µl MTT dye solution (5.0 mg/ml) was mixed with 180 µl medium and added to each well. After incubation at 37°C for 4 h, the culture medium was wiped out and the cells were lysed with DMSO to dissolve the formazan crystals. The optical density (OD) of each well was evaluated at 490 nm wavelength using a 96-well microplate reader (Bio-Rad, Hercules, CA, USA). The growth inhibitory rate was calculated as: [(OD 490_control cells - OD 490_treated cells)/OD 490_control cells] x 100. The experiments were performed in triplicate.

Wound healing assay. Wound healing assay was performed to detect the effect of thymoquinone on cell migration. Prostate cancer DU145 or PC3 cells were seeded onto 6-well plates. When the cell density reached above 90%, scratch wounds were made across the monolayer using the tip of a 200-µl pipette. Then, the wounded cultures were incubated in a serum-free medium with thymoquinone treatment at different times (0, 24 h), and five random fields (magnification, x100) were subsequently chosen from each scratch wound and observed by microscopy to evaluate the migratory capacity. The experiments were performed in triplicate.

Transwell migration assay. Transwell migration assay is another method to evaluate cell migratory ability. It was performed using prostate cancer DU145 and PC3 cells after thymoquinone treatment. Cells (4x10^4) with 200 µl serum-free medium were seeded onto the upper chamber, while 800 µl of medium supplemented with 10% fetal calf serum was added to the lower chamber. After certain incubation at 37°C, the adherent cells on the top chambers were wiped off with a cotton swab. The migrated cells on the lower surface of the filter were then fixed with 4% paraformaldehyde and stained with 0.1% crystal violet (Beyotime, Shanghai, China). Cells were then counted in five randomly chosen visual fields using a microscope at a magnification of x100. The experiments were performed in triplicate.

Matrigel invasion assay. The impact of thymoquinone on the invasion of prostate cancer cells was evaluated by Matrigel invasion assay using a Millicell chamber (Millipore, Billerica, MA, USA). The membrane (polycarbonate membrane, 8 µm pore size) in the top chamber was pretreated with 50 µl Matrigel (Matrigel, serum-free medium 1:5). After incubation at 37°C for 5 h, the cells (10x10^4) in 200 µl serum-free medium were treated with thymoquinone according to the instructions of the Transwell migration assay.

Quantitative real-time PCR assay. DU145 and PC3 cells were treated with different concentrations of thymoquinone and the total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. Complementary DNA (cDNA) was subsequently synthesized using a PrimerScript RT reagent kit (Takara, Dalian, China). Then, the relative levels of target gene messenger RNA (mRNA) transcript were measured by quantitative real-time PCR assay (qRT-PCR) using the SYBR-Green Master Mix. The sequences of primers for the PCR amplification were forward, 5'-GGCCAGATCCGTCCAAGC-3' and reverse, 5'-GTCGCGCTATCCACATTGCAC-3' for TGF-β (201 bp); forward, 5'-CGTCCCATCTGTGACTCCAGC-3' and reverse, 5'-CTCACTCATCTACGTCCTG-3' for Slug (182 bp); forward, 5'-GGCAGGGAAAAATAGG-3' and reverse, 5'-GGGTCTCAGGGAAATAGG-3' for E-cadherin (119 bp); forward, 5'-GACGCCATCACACCCAGGT-3' and reverse, 5'-CTTTGCTGGTTGATTAGCTGGT-3' for vimentin (238 bp); forward, 5'- CGAAGCTGACGACATACAGTG-3' and reverse, 5'-CGAAGCTGACGACATACAGTG-3' for β-actin (250 bp). All the experiments were performed in triplicate and calculated on the basis of the ΔΔCt method. The n-fold change in mRNA expression was evaluated according to the method of 2^ΔΔCt.

Western blotting. Briefly, prostate cancer DU145 and PC3 cells were collected after thymoquinone treatment, and lysed on ice for 10 min with a lysis buffer [10 mmol/l Tris-HCl (pH 7.4), 150 mmol/l NaCl, 0.1% sodium dodecyl sulfate (SDS), 1 mmol/l ethylenediaminetetraacetic acid, 1 mmol/l ethylene glycol tetraacetic acid, 0.3 mmol/l phenylmethylsulfonyl fluoride, 0.2 mmol/l sodium orthovanadate, 1% NP-40, 10 mg/ml leupeptin and 10 mg/ml aprotinin]. After centrifugation and denaturation, the clarified protein lysates (~30-60 µg) were subjected to SDS-polyacrylamide gel electrophoresis (10 or 15%) and transferred to polyvinylidene membranes (Millipore). Membranes were subsequently probed with antibodies against TGF-β, Smad2, Smad3, E-cadherin, vimentin, Slug and β-actin overnight at 4°C. The immunoreactive bands
were then washed and incubated with horseradish peroxidase (HRP)-conjugated secondary antibody at room temperature (25°C). Ultimately, the protein bands were visualized with ECL substrate and exposed to X-ray film.

**Plasmid transfection.** TGF-β cDNA was cloned into the pcDNA3.1 vector. When prostate cancer DU145 or PC3 cells reached 70‑80% confluency for plasmid transfection, the cells were then transfected with X-tremeGENE HP DNA transfection reagent (Roche, Mannheim, Germany) for 48 h following the manufacturer’s instructions, and prepared for the subsequent turnover experiments.

**Statistical analysis.** All statistical analyses were evaluated by GraphPad Prism (version 5.0) software (GraphPad Software, Inc., La Jolla, CA, USA), and Student’s t-test (two-sided) was used for comparisons involving only two groups. A value of \( P<0.05 \) was identified as a statistical significant difference.

**Results**

**Thymoquinone inhibits the proliferation of prostate cancer cells.** Firstly, the chemical structure of thymoquinone is presented in Fig. 1A. In view of the metastatic potential, DU145 and PC3 cells were chosen for the next research. Subsequently, to exclude the effect of thymoquinone on growth inhibition in prostate cancer cells, a modified MTT assay was used. The results demonstrated that the growth of prostate cancer DU145 and PC3 cells at a density >90% was notably repressed upon thymoquinone treatment at concentrations ≥10.0 µM (Fig. 1B-E). Thymoquinone at 10 µM was used as the adequate concentration in the subsequent research, to exclude interference from growth inhibition by thymoquinone.

**Thymoquinone (TQ) inhibits the migratory and invasive capacity of prostate cancer DU145 and PC3 cells.** To explore the effect of thymoquinone on migratory and invasive abilities in prostate cancer cells, a wound healing assay was used to verify the antimitastatic effect of thymoquinone. The results indicated that the scratch width was much wider upon thymoquinone treatment than that in the control group in the DU145 and PC3 cells, suggesting the effective antimitastatic activity of thymoquinone on prostate cancer cells (Fig. 2A and B). To further confirm the effects of thymoquinone on the metastatic phenotype of prostate cancer cells, Transwell migration and Matrigel invasion assays were carried out. We found that the migratory ability of DU145 cells was significantly decreased by thymoquinone treatment (\( P<0.05 \)) (Fig. 2C). Similar results were noted in the prostate cancer PC3 cells treated with thymoquinone (Fig. 2D). Next, we explored the effect of thymoquinone on the invasiveness of prostate cancer cells and our findings indicated that thymoquinone significantly suppressed the invasive capability of the DU145 and PC3 cells (\( P<0.05 \)) (Fig. 2C and D).

Taken together, the results from the wound healing and Transwell assays revealed that thymoquinone had a strong antimitastatic effect on human prostate cancer cells.

**Thymoquinone represses the expression of EMT markers in prostate cancer cells.** EMT has been widely reported to be associated with the ability of migration and invasion in various cancers. In view of that, we first examined the expression levels of EMT markers including E-cadherin, vimentin and Slug by quantitative real-time PCR after treatment of DU145 and PC3 cells with 2.5, 5.0 and 10 µM thymoquinone for 24 h. We found that the mRNA level of E-cadherin was notably upregulated in a concentration-dependent manner, whereas the expression levels of vimentin and Slug at mRNA levels were significantly downregulated (\( P<0.05 \))
Consistent with the above results, western blot analysis showed that thymoquinone decreased the expression levels of the mesenchymal markers including vimentin and Slug, while treatment with thymoquinone increased the expression of E-cadherin (Fig. 3C and D) in the DU145 and PC3 cells. The results revealed that thymoquinone reversed EMT in prostate cancer cells.

Thymoquinone suppresses the expression of epithelial-mesenchymal transition markers in prostate cancer cells. Quantitative real-time PCR was used to examine the expression of E-cadherin, vimentin, Slug and β-actin in prostate cancer (A) DU145 and (B) PC3 cell lines. "P<0.01, ""P<0.001 and """"P<0.0001. (C) DU145 and (D) PC3 cells treated with thymoquinone were subjected to western blotting for E-cadherin (E-Ca), vimentin, Slug and β-actin. Representative protein bands from three experiments are shown.

(Fig. 3A and B). Consistent with the above results, western blot analysis showed that thymoquinone decreased the expression levels of the mesenchymal markers including vimentin and Slug, while treatment with thymoquinone increased the expression of E-cadherin (Fig. 3C and D) in the DU145 and PC3 cells. The results revealed that thymoquinone reversed EMT in prostate cancer cells.

Thymoquinone reduces the expression of TGF-β, Smad2 and Smad3 in prostate cancer cells. Studies have shown that the
TGF-β signaling pathway is implicated in cancer invasion, metastasis and angiogenesis (16). To validate the underlying mechanism involved in the antimitastatic effect of thymoquinone in prostate cancer cells, we detected the expression levels of TGF-β, Smad2 and Smad3 in prostate cancer cells upon thymoquinone treatment. Notably, thymoquinone down-

Figure 4. Thymoquinone reduces the expression of TGF-β, Smad2 and Smad3 in prostate cancer cells. (A and B) Quantitative real-time PCR was used to examine the expression of TGF-β, Smad2 and Smad3 in prostate cancer (A) DU145 and (B) PC3 cells. Furthermore, TGF-β, Smad2 and Smad3 levels in prostate cancer (C) DU145 and (D) PC3 cells treated with thymoquinone were determined by western blotting.

Figure 5. Overexpression (OE) of TGF-β attenuates the antitumor capacity of thymoquinone (TQ) in prostate cancer cells. Transwell migration and Matrigel invasion assays were performed on (A) DU145 and (B) PC3 cells following combination treatment of TQ and TGF-β overexpression. Five random fields were chosen and visualized by microscopy to assess the cell migratory and invasive capacity. Western blotting was performed to evaluate the levels of TGF-β, Smad2, Smad3, E-cadherin (E-Ca), vimentin and β-actin protein upon various treatments in the (C) DU145 and (D) PC3 cells. Representative protein bands of three experiments are shown.
regulated TGF-β, Smad2 and Smad3 expression at the mRNA level in a concentration-dependent manner (Fig. 4A and B). In accordance with the above results, the protein levels of TGF-β, Smad2 and Smad3 in the DU145 and PC3 cells were significantly reduced following thymoquinone treatment (P<0.05) (Fig. 4C and D).

Overexpression of TGF-β attenuates the antitumor capacity of thymoquinone in prostate cancer cells. To further explore whether the TGF-β signaling pathway is involved in the antimetastatic effect of thymoquinone on prostate cancer cells, the TGF-β plasmid was transiently transfected into DU145 and PC3 cells to overexpress TGF-β. Intriguingly, overexpression of TGF-β partially restored the migratory and invasive capacities of the prostate cancer cells, which was inhibited by thymoquinone (Fig. 5A and B). These findings suggested that TGF-β may play a crucial role in the antimetastatic activity of thymoquinone in prostate cancer.

Subsequently, we found a marked reversal of the elevated E-cadherin level, and reduced vimentin, Smad2 and Smad3 levels following the combined treatment of thymoquinone and TGF-β overexpression, compared with thymoquinone treatment alone (Fig. 5C and D). These results revealed that the antimetastatic capacity of thymoquinone in prostate cancer may be mediated by the TGF-β signaling pathway.

Discussion
Numerous studies have shown that thymoquinone is able to impede tumor progression in a variety of tumors. It is reported that in prostate cancer PC3 cells, thymoquinone may suppress tumor angiogenesis and growth by downregulating AKT and extracellular signal-regulated kinase (ERK) signaling (17). Additionally, thymoquinone notably suppressed DNA synthesis and proliferation in prostate cancer LNCaP, C4-2B, DU145 and PC3 cell lines via inactivation of the androgen receptor (AR) and E2F1, a regulator of cell viability (18). In addition, it has been found that thymoquinone could potentiate the cytotoxic and pro-apoptotic effect of zoladexic acid (ZA) in prostate cancer PC3 and DU145 cells (19). In the present study, we indeed confirmed the cytotoxic effect of thymoquinone on prostate cancer DU145 and PC3 cells. The subsequent wound healing and Transwell assays revealed that thymoquinone notably suppressed the metastatic phenotype of prostate cancer cells. Then, we detected the mRNA and protein levels of E-cadherin, vimentin and Slug, hallmarks of epithelial-to-mesenchymal transition (EMT). As expected, thymoquinone significantly increased the expression of E-cadherin, while decreased the expression of vimentin and Slug at the mRNA and protein levels using quantitative real-time PCR and western blotting, suggesting that thymoquinone reversed EMT in prostate cancer DU145 and PC3 cells. Meanwhile, other studies have demonstrated that thymoquinone decreased the expression of Twist1 at the transcriptional level, leading to the reversal of EMT in MDA-MB-435, BT549 and HeLa cells. In addition, thymoquinone downregulated N-cadherin, Snail and Slug expressions in bladder cancer T24 cells, which were partially in accordance with our results (20).

The TGF-β signaling pathway has been confirmed to regulate malignancy progression and metastasis (21). It is reported that TGF-β may participate in the regulation of collagen (22), fibronectin (23), laminin (24) and MMP-9 (25), to affect migratory and invasive capacity. Accumulating evidence shows that Chinese herbal medicines, such as curcumin and anthocyanidins, reverse EMT and suppress metastasis via the downregulation of the TGF-β/Smad2/3 signaling pathway (26,27). Our findings revealed a marked dose-dependent reduction in TGF-β, Smad2 and Smad3 levels upon thymoquinone treatment in prostate cancer DU145 and PC3 cells, which was confirmed by quantitative real-time PCR and western blotting. To further validate that the TGF-β/Smad2/3 signaling pathway participates in the reversal of EMT by thymoquinone in prostate cancer, a TGF-β overexpression plasmid was transiently transfected into DU145 and PC3 cells. The results demonstrated that overexpression of TGF-β impaired the antimetastatic effect of thymoquinone and partially abrogated the induction of mesenchymal-to-epithelial transition (MET) by thymoquinone, as evidenced by the reversal of the elevated E-cadherin level and decreased vimentin, Smad2 and Smad3 levels. These results indicated that the inhibitory effect of thymoquinone on EMT may be mediated by the TGF-β/Smad2/3 signaling pathway.

In summary, our study confirmed that thymoquinone suppressed the metastatic phenotype and inhibited EMT in prostate cancer cells by negatively regulating the TGF-β/Smad2/3 signaling pathway. In addition, these findings suggest that thymoquinone is a potential therapeutic agent against prostate cancer which functions by targeting TGF-β.

Acknowledgements
The present study was partially supported by the National Natural Science Foundation of China (no. 81602562), the International Science and Technology Cooperative Project of Shaanxi Province (no. 2017KW-063), the Fundamental Research Funds for the Central University of Xi'an Jiaotong University (no. 1191329722), and the Institutional Scientific Development Foundation of the First Affiliated Hospital of Xi'an Jiaotong University (no. 2015YK17).

References


